Clinical Trial Detail

NCT ID NCT03416335
Title A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Boston Biomedical, Inc
Indications

lung non-small cell carcinoma

stomach cancer

melanoma

cervical cancer

hepatocellular carcinoma

Advanced Solid Tumor

Merkel cell carcinoma

head and neck squamous cell carcinoma

transitional cell carcinoma

Therapies

DSP-0509

DSP-0509 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.